Supervisor: VS 高志平 Reporter: R4 張妙而.  Mutations in nucleophosmin 1 ( NPM1 ) gene, one of the most common gene mutations (25%-30%) in AML  NPM1 mut co-occurs.

Slides:



Advertisements
Similar presentations
Susanna Akiki WMRGL 2009 Acute Promyelocytic Leukemia with t(15;17) (q22;q21) developing inv(16)(p13q22) secondary AML.
Advertisements

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Targeted Therapy in Acute Myeloid Leukemia
Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.
台北榮總血液腫瘤科 楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN.
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
Acute Myeloid Leukemia
A schematic comparison is shown of the highly coordinated and quantitatively regulated hierarchy of normal tissue populations in which cell turnover is.
Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010.
GeneSequenceTa °CFunction IDH1 exon 4 Fw5'-AGCTCTATATGCCATCACTGC-3' 62 Methylation Rv 5 ’ -AACATGCAAAATCACATTATTGCC-3 ’ IDH2 exon 4 Fw 5 ’ -AATTTTAGGACCCCCGTCTG-3.
Current Status of Acute Myeloid Leukemia in China Jianxiang Wang Institute of Hematology Hospital of Blood Disease Chinese Academy of Medical Sciences.
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Analyzing DNA using Microarray and Next Generation Sequencing (1) Background SNP Array Basic design Applications: CNV, LOH, GWAS Deep sequencing Alignment.
FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
R2 김재민 / Prof. 윤휘중 Journal conference 1.
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.
May 29 - June 2, 2015 Leukemia Stem Cell Phenotypes Correlate With Cytogenetic Risk Factors and Outcomes CCO Independent Conference Highlights of the 2015.
Identification of mutations prognostic of relapse after allogeneic transplantation and novel clone emergence at disease recurrence: implications for strategies.
39th ESMO Congress Madrid, Spain – 30 September Poster 979P
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Maury S et al. Proc ASH 2015;Abstract 1.
  PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE LOCI OF GENE VARIANCES PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE.
Advances in the Management of Pediatric Acute Leukemia
Stems Cells and the Pathways to Aging and Cancer
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
at First Pavlov State Medical University of Saint-Petersburg, Russia
Clearance of ‘Driver-COSMIC’ mutations post-CR1 with persisting RUNX1_L56S is unlikely to contribute towards disease progression L . Rai1, T. Boneva1,
FLT3 Internal Tandem Duplication(ITD) mutation in Acute Myeloid Leukemia and its clincopathological correlation – Study from a tertiary care centre in.
Goede V et al. Proc ASH 2014;Abstract 3327.
by David Grimwade, Adam Ivey, and Brian J. P. Huntly
Mutations and AML: Sampling, Assays, and Interpreting Results
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Darwinian evolution and tiding clones in multiple myeloma
European Focus on MPN and MDS 2014
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.
Adrian G. Selim, Andrew S. Moore  The Journal of Molecular Diagnostics 
Epigenetic heterogeneity is associated with genetic heterogeneity in CLL samples. Epigenetic heterogeneity is associated with genetic heterogeneity in.
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
by R. Coleman Lindsley, and Benjamin L. Ebert
Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation  Miguel Waterhouse, Dietmar Pfeifer, Milena Pantic,
Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.
Grövdal M et al. Blood 2008;112:Abstract 223.
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,
New ELN Recommendations
Short title / Key scientific finding
Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.
MRD = Minimal Resistant Disease?
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia by Jianting Long, Brian.
Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia  Aaron T. Gerds, Matthew J. Walter, Bart L. Scott 
On the Origin of Leukemic Species
Neoplastic disorder.
Genetic and Functional Diversity of Propagating Cells in Glioblastoma
1Kantarjian HM et al. Lancet Oncol 2011;12:
Iléana Antony-Debré, Ulrich Steidl  Cancer Cell 
Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018
Timing for HCT Consultation
How I treat T-cell acute lymphoblastic leukemia in adults
Stems Cells and the Pathways to Aging and Cancer
Presentation transcript:

Supervisor: VS 高志平 Reporter: R4 張妙而

 Mutations in nucleophosmin 1 ( NPM1 ) gene, one of the most common gene mutations (25%-30%) in AML  NPM1 mut co-occurs with FLT3, DNMT3A, IDH1, IDH2, and NRAS, not in a random order, instead early and late events

 A high proportion of NPM1 mut AML patients achieve CR with intensive chemotherapy  50% of these patients have relapse during the first 3 years after diagnosis, in particular with concurrent FLT3-ITDs gene

 NPM1 mut, founder event in the pathogenesis of AML, based on stable over time and maintained at relapse, even after a long latency  Loss of NPM1 mut in 10% of relapsed patients, accompanied by chromosomal and molecular changes

 Clonal evolution is a hallmark of cancer, highly affected by cytotoxic therapy, selecting resistant clones, reoccurrence of the disease  To assess clonal evolution in “AML with NPM1 mut,” the author analyzed paired leukemia samples at diagnosis and relapse from 53 patients by high- resolution SNP-array profiling and mutation analysis of 10 AML-associated genes SNP: single-nucleotide polymorphism

 53 adult AML patients (24-66 y/o)

 CNA: copy number alterations, UPD: uniparental disomies 11/53 2/53 17/53 6/53 Mean number of abberations 0.28 per case/diagnosis to 1.06 per case/relapse (paired Student t test, P=0.002)

The same Del(9q) lost

N=3, both N=1, diagnosis only N=7, relapse only

 Stability = mutations persisted in relapse/all mutations in diagnosis  Acquired at relapse = new mutations in relapse/ mutations in diagnosis

CIR=cumulative incidence of relapse The median time interval between achievement of CR and relapse in these 5 AML cases was 33.7 months (range, months) and thus significantly longer than in the 48 patients maintaining the NPM1 mutation at relapse (median, 8.6 months; range, ; P=0.03)

Additional aberration Lost aberration Newly acquired gene

 High-resolution SNP-array profiling of 53 relapsed NPM1 mut AML patients  0.28 aberration/case at diagnosis  1.06 aberration/case at relapse  A higher genetic complexity at relapse is consistent with previous by chromosomal banding analysis

 Most of aberrations found at relapse, associated with high-risk AML, part explain the poor outcome of relapsed AML  No evidence for t-AML that derived from a genetically unrelated hematopoietic clone  Primary leukemia and relapse, genetically related and derive directly from the dominant leukemic clone or from a common ancestral clone

Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382):

Gain mutations Survive and expand

 DNA-damaging chemotherapy causes secondary genetic changes in persisting (pre-)leukemic clones  The specific alterations exclusively at relapse, such as 27/del(7q) and derivative chromosome (12;17)(q10;q10), are frequent in previously treated with chemotherapy

 A marked increase in the number of a specific type of mutation (transversions) in relapsed AML compared with de novo AML  In conclusion, although NPM1 mut is generally considered a primary event in NPM1 mut AML, the data of this study suggest that mutations in DNMT3A can precede NPM1 mutations.

 Persisting subclones or preleukemic HSCs acquire new secondary aberrations rather than being genetically unrelated t-AML  To achieve long-term leukemia-free survival, future therapies in AML need to eradicate all (pre-)leukemic clones present at diagnosis that persist during therapy and contribute to relapse